Last Updated on September 3, 2026 by Dr. Bhagat
Nature Reviews Clinical Oncology’s 2025 Journal Impact Factor is 94.6, reported in the 2026 Journal Citation Reports release. The journal is placed in Q1 in its relevant category and is indexed in the Web of Science Core Collection. This page combines the current JIF with the publisher’s 2025 journal metrics, historical context and practical publication guidance.
2026 data update
Journal Impact Factor year: 2025 · JCR release year: 2026 · Current JIF: 94.6 · Quartile: Q1
Nature Reviews Clinical Oncology metrics at a glance
| Metric | Current value |
|---|---|
| 2025 Journal Impact Factor | 94.6 |
| 5-year Journal Impact Factor | 105.2 |
| JCR category | Oncology |
| Best JCR quartile | Q1 |
| Web of Science coverage | SCIE |
| SCImago Journal Rank (2025) | 28.076 |
| Median submission to first editorial decision | 4 days |
| Median submission to acceptance | 122 days |
| Publishing model | Nature Reviews journal whose core review content is published through the subscription route |
Source: Nature Reviews Clinical Oncology’s official journal-metrics page. Citation metrics and editorial-speed figures are labelled for 2025 by the publisher.
About Nature Reviews Clinical Oncology
Nature Reviews Clinical Oncology is a Nature Portfolio journal covering clinical cancer research, systemic treatment, radiotherapy, surgery, biomarkers, trial design, survivorship and supportive care. Its value to readers comes from editorially selected work that connects major developments, evidence and open questions across the field.
The journal-level metrics on this page describe the publication as a whole. They do not predict the citation count, methodological quality or practical importance of an individual paper.
What is Nature Reviews Clinical Oncology’s Impact Factor in 2025?
The 2025 Journal Impact Factor is 94.6. This is the current value displayed by Nature Portfolio. The corresponding five-year Journal Impact Factor is 105.2, which uses a longer citation window and can be useful for fields in which citations accumulate gradually.
Why the 2025 JIF appears in JCR 2026
The metric is named for the citation year, while Journal Citation Reports releases it in the following year. Therefore, “2025 Journal Impact Factor” and “2026 JCR release” refer to the same current reporting cycle.
Is Nature Reviews Clinical Oncology a Q1 and SCIE-indexed journal?
Yes. Nature Reviews Clinical Oncology is placed in Q1 in its relevant Journal Citation Reports category and is covered by the Science Citation Index Expanded (SCIE).
Quartiles are category-specific. A Q1 result means the journal sits in the highest quartile under the relevant category ranking; it should not be used as a universal comparison between unrelated disciplines.
Nature Reviews Clinical Oncology Impact Factor trend, 2017–2025
| Impact Factor year | Journal Impact Factor | Year-on-year change |
|---|---|---|
| 2017 | 24.653 | — |
| 2018 | 34.106 | +38.3% |
| 2019 | 53.276 | +56.2% |
| 2020 | 66.675 | +25.2% |
| 2021 | 65.011 | -2.5% |
| 2022 | 78.8 | +21.2% |
| 2023 | 81.1 | +2.9% |
| 2024 | 82.2 | +1.4% |
| 2025 | 94.6 | +15.1% |
The latest movement is from 82.2 in 2024 to 94.6 in 2025 (+15.1%). “Not reported” is used where the journal did not yet have a Journal Impact Factor; no value has been invented for those years.
Scope and readership
The journal focuses on clinical cancer research, systemic treatment, radiotherapy, surgery, biomarkers, trial design, survivorship and supportive care. Prospective authors should compare the specific question, audience and article type with the journal’s current aims and scope rather than relying on the Impact Factor alone.
Because Nature Portfolio journals serve international audiences, manuscripts and proposals should explain why the topic matters now, what evidence is being synthesized or presented, and which readers outside the narrowest specialty will benefit.
Article types and editorial model
Nature Reviews Clinical Oncology is not a conventional destination for unsolicited primary-research papers. Much of its long-form review content is commissioned by the editors. Researchers with a timely review idea should check the current proposal and author guidance before preparing a full manuscript; an unsolicited proposal is not an acceptance commitment.
Article-type names and requirements can change. Authors should use the current journal website, not an old third-party checklist, for word limits, figure limits, reporting standards and proposal instructions.
Editorial decision and publication time
The publisher reports a 2025 median of 4 days from submission to the first editorial decision and 122 days from submission to acceptance. These medians are descriptive journal-level statistics, not promised turnaround times.
Submission-to-acceptance time can include editorial assessment, external review, author revision and further checks. The duration for a particular manuscript can be shorter or longer.
Acceptance rate
Nature Reviews Clinical Oncology does not publish a dependable current acceptance-rate percentage on its public journal-metrics page. This article therefore does not provide an estimated or third-party acceptance rate. For review journals, the commissioned editorial model also makes a simple acceptance-rate comparison with ordinary research journals potentially misleading.
Open access and publication fees
Nature Portfolio states that articles in the Nature Reviews journals use the subscription publication route rather than an immediate gold open-access option. Authors should still check the current publishing-model page because licensing and access policies can change.
Do not treat a fee shown by an aggregator as authoritative. Confirm the applicable route, currency, taxes, funder rules and institutional agreements directly with the publisher before submission.
How to judge whether the journal fits your work
- Read the current aims and scope and several recently published articles.
- Confirm that your proposed article type is actually accepted by the journal.
- Explain the topic’s importance, timeliness and relevance to the journal’s readership.
- Check data, ethics, reporting and competing-interest requirements.
- Verify the latest access route, licence and any applicable publication charge.
How to interpret the Impact Factor responsibly
A JIF of 94.6 indicates strong recent citation activity at journal level. It does not mean that every paper will receive 94.6 citations. Citation distributions are uneven, and review articles often accumulate citations differently from original research.
For submission and evaluation decisions, use the JIF together with scope, editorial fit, peer-review practices, article-level evidence, openness, cost and the needs of the intended audience.
Frequently asked questions
What is Nature Reviews Clinical Oncology’s 2025 Impact Factor?
The current 2025 Journal Impact Factor is 94.6, reported in the 2026 JCR release.
What is the five-year Impact Factor?
Nature Portfolio reports a 2025 five-year Journal Impact Factor of 105.2.
Is Nature Reviews Clinical Oncology Q1?
Yes. It is placed in Q1 in its relevant Journal Citation Reports category.
Is the journal indexed in SCIE?
Yes. Nature Reviews Clinical Oncology is covered by the Science Citation Index Expanded.
How fast is the first editorial decision?
The 2025 publisher-reported median is 4 days. This is a median, not a guarantee for an individual submission.
What is the acceptance rate?
No dependable current percentage is published on the official metrics page, so this article does not present an unofficial estimate as fact.
Sources and data notes
- Nature Reviews Clinical Oncology: official journal metrics
- Nature Portfolio editorial policies
- Clarivate Journal Citation Reports
Data checked: 3 September 2026. Current metrics were checked against Nature Portfolio’s journal-metrics pages. Historical values are labelled by metric year. Fees and operational metrics can change, so readers should confirm them with the journal.
